Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned a consensus rating of “Moderate Buy” from the twenty-two brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twenty have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $118.90.

KYMR has been the topic of a number of recent analyst reports. Mizuho boosted their price objective on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Morgan Stanley restated an “overweight” rating and set a $123.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Citigroup lifted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Stifel Nicolaus set a $114.00 price target on Kymera Therapeutics in a research note on Monday, December 8th. Finally, UBS Group increased their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd.

Kymera Therapeutics Stock Down 1.2%

Shares of NASDAQ:KYMR opened at $76.96 on Tuesday. The company has a market capitalization of $6.28 billion, a price-to-earnings ratio of -20.91 and a beta of 2.20. The company has a 50 day moving average of $79.79 and a two-hundred day moving average of $70.08. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.88) earnings per share. On average, equities analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Jeremy G. Chadwick sold 25,758 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $83.30, for a total transaction of $2,145,641.40. Following the completion of the sale, the chief operating officer owned 68,052 shares of the company’s stock, valued at approximately $5,668,731.60. This trade represents a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jared Gollob sold 5,613 shares of Kymera Therapeutics stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $88.93, for a total transaction of $499,164.09. Following the completion of the sale, the insider owned 122,029 shares of the company’s stock, valued at approximately $10,852,038.97. This trade represents a 4.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 196,561 shares of company stock worth $17,097,428 over the last 90 days. 16.01% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC grew its holdings in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics in the 4th quarter valued at about $63,000. PNC Financial Services Group Inc. lifted its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.